Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVM150 and CVM26 Intranasal Mumps Vaccines in Healthy Adults
NCT06967181Phase 1Active, not recruiting
- Sponsor
- CyanVac LLC
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CVM150 and CVM26 in mumps, sponsored by CyanVac LLC. Primary endpoints: Solicited local reactogenicity symptom pertaining to intranasal administration at 8 days, Solicited systemic reactogenicity symptom at 8 days and 3 more. Started May 2025; status: active, not recruiting.
02
Drugs
CVM150CVM26
03
Conditions
mumps
Beyond the preview
Go deeper on NCT06967181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06967181.